Refined BUS TI-RADS 2.0 reclassifies vascularity to boost thyroid nodule risk stratification accuracy

BUS TI-RADS 2.0 achieved AUC 0.98 for thyroid nodule malignancy, outperforming ACR TI-RADS (0.94) and C-TIRADS (0.93), with a 12.98% false-negative rate and 2.97% biopsy recommendation rate.

• Internal/external validation AUCs were 0.96 and 0.94, comparable to original BUS TI-RADS but significantly higher than ACR and C-TIRADS (P<0.001).
• Broader adoption depends on validating consistency across unselected cases and varying reader expertise, the authors note.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.